Lipoprotein(a)
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- Lp(a) is the most common genetic cardiovascular risk factor you've likely never been tested for. 1 in 5 people have elevated levels, and most have no idea — because it is almost never included in standard care panels.
- Lp(a) is largely immune to lifestyle modification. Unlike almost every other biomarker in this library, diet, exercise, and weight loss have minimal effect on Lp(a). It is set by your genetics.
- High Lp(a) doubles or triples cardiovascular risk — but that risk is meaningfully modified by how aggressively you control everything else. Knowing your Lp(a) changes the urgency of managing LDL, blood pressure, and inflammation.
- Measure it once. Lp(a) levels are stable throughout adult life. One measurement at any age provides the information you need. Retesting is generally unnecessary unless a major life event warrants reassessment.
- Targeted Lp(a) therapies are coming. Multiple RNA-based medications (including pelacarsen and olpasiran) have shown 80–90% Lp(a) reductions in phase 2 trials. Phase 3 cardiovascular outcomes trials are underway. For people with high Lp(a), this is a treatment landscape that may change dramatically within 2–5 years.
The Most Important Cardiovascular Test Most People Have Never Had
Lipoprotein(a) is not a new discovery. Its association with cardiovascular disease has been recognized for decades, and it has appeared in cardiovascular research literature since the 1960s. Yet despite affecting approximately 20% of the population and conferring a 2–3-fold increase in heart attack risk, Lp(a) is not included in standard cholesterol panels, is not routinely ordered by most primary care physicians, and is not mentioned in most people's annual health reviews.
The practical consequence is that approximately 60–65 million Americans are walking around with meaningfully elevated cardiovascular risk from Lp(a) and have never been told. Many are in the perplexing situation of maintaining healthy LDL, blood pressure, and lifestyle — and still experiencing premature heart attacks — with an unmeasured Lp(a) as the underlying explanation.
The case for measuring Lp(a) at least once is unambiguous. It costs $30–50, is drawn from a standard blood sample, needs to be measured only once in a lifetime, and provides information that changes clinical decision-making: how aggressively to target LDL, whether coronary calcium scoring is warranted, and how urgently to address every other modifiable risk factor. The European Atherosclerosis Society, the American Heart Association, and virtually every major lipidology society recommend at least one Lp(a) measurement in all adults.
Why Lp(a) Is Particularly Dangerous: The Dual Mechanism
Most atherogenic lipoproteins cause cardiovascular disease primarily by depositing cholesterol in arterial walls — a slow process unfolding over decades. Lp(a) is more dangerous than LDL in part because it operates through two distinct pathways simultaneously.
Atherogenesis (plaque formation): Lp(a) carries a cholesterol-rich lipid core identical to LDL and penetrates arterial walls through the same mechanisms. It accumulates in plaques, is oxidized, and promotes the macrophage foam cell formation that drives atherosclerosis progression. Epidemiological studies show that aortic stenosis — calcification and narrowing of the aortic valve — is one of the most striking Lp(a)-related conditions, with high Lp(a) carriers having dramatically elevated risk for this otherwise poorly-understood condition.
Thrombogenesis (clot formation): The apo(a) protein attached to Lp(a) particles is structurally homologous to plasminogen — the precursor to plasmin, the body's primary clot-dissolving enzyme. Apo(a) competes with plasminogen for binding sites and inhibits plasmin activity, impairing the fibrinolytic system that would normally dissolve clots after they form. This is critically important in the context of a ruptured plaque: when an atherosclerotic plaque breaks open, the exposed material triggers rapid clot formation. In the presence of high Lp(a), the clot that forms is harder to dissolve, dramatically increasing the likelihood that it will cause a complete arterial occlusion — a heart attack or stroke.
This dual mechanism — accelerating plaque formation AND impairing clot resolution — explains why Lp(a) carries disproportionate cardiovascular risk relative to its absolute atherogenic burden.
Understanding the Genetics: Why Lifestyle Doesn't Move the Needle
Approximately 90% of the variation in Lp(a) levels across individuals is genetic — determined primarily by variants in the LPA gene that control how much apo(a) the liver produces. The size of the apo(a) isoform (determined by the number of kringle-IV type 2 repeats in the LPA gene) inversely predicts Lp(a) levels: people with smaller apo(a) isoforms produce more apo(a) and have higher Lp(a) concentrations.
This genetic determination is why the usual lifestyle toolkit — improving diet, losing weight, exercising more — produces essentially no meaningful change in Lp(a). The liver is simply programmed to produce a certain amount, and dietary or exercise signals don't override that programming. This is fundamentally different from LDL, which responds dramatically to diet (saturated fat reduction), exercise, and statin therapy, or triglycerides, which can be cut in half within weeks of carbohydrate reduction.
For people accustomed to having agency over their biomarkers, this is often frustrating to hear. The reframe is important: knowing your Lp(a) is not about changing it through willpower or discipline. It is about knowing your baseline risk so you can prioritize what is changeable — and so you are positioned to benefit from targeted Lp(a)-lowering therapies when they become available.
| Lp(a) (mg/dL) | Risk Classification | Approximate Population % | Cardiovascular Risk Implication |
|---|---|---|---|
| < 30 | Desirable | ~50% | No additional Lp(a)-related cardiovascular risk |
| 30–50 | Borderline | ~30% | Modestly elevated risk; optimize other factors |
| 50–100 | High | ~15% | ~2x elevated CVD risk; aggressive risk factor management |
| > 100 | Very high | ~5% | ~3x+ elevated CVD risk; cardiology involvement warranted |
Already have your lab results? See how your Lp(a) and other cardiovascular markers score on a longevity scale — in under 60 seconds.
Analyze My Biomarkers →What to Do With a High Lp(a) Result
Receiving a high Lp(a) result is not a verdict — it is information that enables better decision-making. The clinical response unfolds across several dimensions.
Aggressively optimize all modifiable risk factors. Lp(a) functions as a risk multiplier that interacts with other cardiovascular risk factors. The absolute risk conferred by high Lp(a) is substantially lower when LDL/ApoB is well controlled, blood pressure is optimal, inflammation is low, and metabolic health is excellent. Conversely, the combination of high Lp(a) plus elevated LDL plus smoking is extraordinarily dangerous. For people with high Lp(a), the LDL/ApoB target should be more aggressive than it would be for someone without elevated Lp(a) — many cardiologists target ApoB below 70 mg/dL or LDL below 70 mg/dL in high-Lp(a) patients rather than the more lenient targets applied to lower-risk individuals.
Consider coronary artery calcium (CAC) scoring. A CAC score measures the amount of calcified plaque in the coronary arteries, providing direct evidence of whether Lp(a) has already caused measurable atherosclerosis. A CAC score of zero is highly reassuring even with high Lp(a) — suggesting the genetic risk has not yet translated into anatomical disease. A high CAC score in a younger person with high Lp(a) supports very aggressive risk factor management and potentially medication. CAC scoring requires a brief low-dose CT scan and costs $75–150 out of pocket at most imaging centers.
Family screening. Because Lp(a) is largely heritable, a high result in one family member warrants consideration of screening in first-degree relatives — parents, siblings, and children. This is particularly important for children, who can benefit from early risk awareness and cardiovascular health optimization before atherosclerosis accumulates.
Monitor the treatment landscape. RNA-interference and antisense oligonucleotide therapies targeting Lp(a) are in late-stage clinical development. Pelacarsen (an antisense therapy) and olpasiran (an siRNA therapy) have both demonstrated 80–90% Lp(a) reductions in phase 2 trials. Large phase 3 cardiovascular outcomes trials are underway. These therapies represent a potentially transformative option for people with high Lp(a), and may become available within 2–5 years. Staying connected to this space — through a lipidologist or informed cardiologist — is worthwhile for anyone with Lp(a) above 50 mg/dL.
A Note on Units: mg/dL vs. nmol/L
Lp(a) is reported in two different units by different laboratories — mg/dL and nmol/L — and these are not interchangeable. The discrepancy arises because apo(a) comes in different sizes (different numbers of kringle-IV repeats), and smaller isoforms pack more particles per unit mass. A concentration measured in mass (mg/dL) reflects both particle number and particle size; nmol/L reflects only particle number.
nmol/L is the preferred unit in cardiovascular research because particle number is the more direct measure of atherogenic risk. The EAS and most research guidelines now recommend nmol/L, with a risk threshold of approximately 125 nmol/L corresponding roughly to 50 mg/dL — though this conversion is approximate and varies by isoform.
Practically: note which unit your lab reports, be consistent when comparing serial results (always same lab, same assay), and if comparing to research studies or guidelines that use different units, confirm the conversion is appropriate for your apo(a) isoform size if possible.
Sources
- Nordestgaard BG, et al. "Lipoprotein(a) as a Cardiovascular Risk Factor: Current Status." European Heart Journal, 2010. PubMed →
- Kamstrup PR, et al. "Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction." JAMA, 2009. PubMed →
- Tsimikas S. "A Test in Context: Lipoprotein(a)." Journal of the American College of Cardiology, 2017. PubMed →
| Range Type | Value (mg/dL or nmol/L) | Notes |
|---|---|---|
| Standard Clinical Range | Desirable: < 30 mg/dL · Borderline: 30–50 mg/dL · High risk: > 50 mg/dL | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | < 30 mg/dL |
Associated with reduced all-cause mortality and extended healthspan.
Risk rises continuously above approximately 30 mg/dL, with particularly sharp increases above 50 mg/dL. Because Lp(a) is largely genetically fixed, the clinical response to a high result is not to lower Lp(a) per se (though niacin and PCSK9 inhibitors have modest effects) but to aggressively manage all other modifiable cardiovascular risk factors: target LDL and ApoB as low as feasible, optimize blood pressure, eliminate smoking, and manage inflammation. Lp(a) need only be measured once or twice in a lifetime.
|
Already have your results? See what your Lipoprotein(a) and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
What Lp(a) level is considered high?
The standard clinical threshold for elevated Lp(a) risk is 50 mg/dL (approximately 125 nmol/L). Above this level, cardiovascular risk — particularly heart attack and aortic stenosis — is meaningfully elevated compared to the general population. However, risk rises continuously above approximately 30 mg/dL, and some guidelines now consider the 30–50 mg/dL range as borderline-elevated. Lp(a) can be reported in either mg/dL or nmol/L — the units are not interchangeable, as apo(a) isoforms vary in size. nmol/L is the preferred unit because it more directly reflects particle number rather than mass. A result of 75 mg/dL may correspond to 125–250 nmol/L depending on apo(a) isoform size. When comparing results or using risk calculators, confirm which units your lab used.
Why can't I lower Lp(a) with diet and exercise?
Lp(a) levels are almost entirely determined by genetic variants in the LPA gene, which encodes the apo(a) protein. The gene controls how much apo(a) the liver produces, which determines circulating Lp(a) concentration. Because the liver produces Lp(a) at a genetically programmed rate that is largely independent of nutritional signals, diet and exercise — which powerfully modulate most other lipid markers — have minimal effects. Studies measuring Lp(a) before and after dietary interventions, weight loss, and intensive exercise programs consistently find less than 10% change. The exceptions are niacin (which lowers Lp(a) by approximately 20–30% but at doses that cause significant side effects and whose cardiovascular benefit has been disappointing in trials) and PCSK9 inhibitors (which lower Lp(a) by 20–30% in addition to their primary LDL-lowering effect). Neither is currently used primarily for Lp(a) management.
What should I do if my Lp(a) is high?
A high Lp(a) result changes your risk calculus but does not leave you without options. The most important responses are: (1) Treat all other modifiable cardiovascular risk factors aggressively — a person with high Lp(a) and well-controlled LDL, blood pressure, and inflammation has substantially lower absolute risk than someone with high Lp(a) and multiple other uncontrolled risk factors. Your ApoB target should be lower than it would be for someone without elevated Lp(a). (2) Eliminate smoking entirely — the cardiovascular risk interaction between smoking and elevated Lp(a) is particularly severe. (3) Discuss with a cardiologist whether coronary artery calcium (CAC) scoring is appropriate to assess whether Lp(a) has already caused measurable plaque. (4) Monitor the therapeutic landscape — multiple Lp(a)-specific treatments are in phase 3 trials and may reach clinical availability within 2–5 years.
What is the difference between Lp(a) and LDL?
LDL and Lp(a) are both lipoprotein particles that carry cholesterol through the bloodstream and contribute to atherosclerosis — but they are structurally and functionally distinct. LDL consists of a lipid core surrounded by ApoB-100 protein and is cleared by LDL receptors in the liver. Lp(a) has the same LDL-like core but with an additional protein, apo(a), attached to the ApoB via a disulfide bond. This apo(a) protein is structurally similar to plasminogen — the body's natural clot-dissolving protein — which gives Lp(a) its additional thrombogenic properties. While LDL primarily drives atherosclerosis by depositing cholesterol in arterial walls, Lp(a) does this AND inhibits fibrinolysis (clot dissolution), making it particularly dangerous when a plaque ruptures and a clot forms — the triggering event for most heart attacks.
Is Lp(a) always harmful at high levels?
The evidence for Lp(a) as a cardiovascular risk factor is among the strongest in lipidology, supported by genetic epidemiology (Mendelian randomization studies that show the relationship is likely causal, not just correlative), large prospective cohort data, and biological mechanistic plausibility. However, it is worth noting that elevated Lp(a) is a risk factor, not a certain predictor of disease. Many people with very high Lp(a) never develop cardiovascular disease, particularly those who control other risk factors diligently. Lp(a) interacts with other risk factors — its impact on absolute risk is larger when combined with elevated LDL, smoking, hypertension, or diabetes than when other factors are well controlled. Knowing your Lp(a) is about calibrating risk and taking appropriate protective action, not about certainty of disease.